- Home
- ALNY vs MCHP Comparison
ALNY vs MCHP Comparison
Compare ALNY & MCHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | MCHP |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 45.7B |
| IPO Year | 2004 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ALNY | MCHP |
|---|---|---|
| Price | $270.80 | $78.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 22 |
| Target Price | ★ $471.00 | $85.59 |
| AVG Volume (30 Days) | 1.5M | ★ 10.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.02% |
| EPS Growth | 206.88 | ★ 2300.00 |
| EPS | ★ 2.33 | 0.22 |
| Revenue | $1,037,418,000.00 | ★ $5,349,500,000.00 |
| Revenue This Year | $52.67 | $8.12 |
| Revenue Next Year | $31.48 | $22.55 |
| P/E Ratio | ★ $116.64 | $358.09 |
| Revenue Growth | 22.88 | ★ 34.38 |
| 52 Week Low | $262.21 | $48.52 |
| 52 Week High | $495.55 | $105.91 |
Technical Indicators
Market Signals| Indicator | ALNY | MCHP |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 38.18 |
| Support Level | N/A | $72.89 |
| Resistance Level | $318.35 | $82.39 |
| Average True Range (ATR) | 15.92 | 3.34 |
| MACD | -3.02 | -0.44 |
| Stochastic Oscillator | 8.17 | 2.57 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About MCHP Microchip Technology Incorporated
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.